The effect of vitamin D on depression, anxiety and general health.

Phase 3

Recruiting

• Conditions: Condition 1: Anxiety. Condition 2: Depression. Condition 3: General health.; Anxiety disorder due to known physiological condition; F06.4

• Registration Number: IRCT20090810002324N18
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

Age 45 to 65 years.
pass of at least one year since the last menstrual period.
Body mass index less than 30 kg/m^2.
Physical and mental health (according to personal reporting)

Exclusion Criteria

Vitamin D level above 30 nmol/L in the first blood sample.
Confirmation of chronic kidney, liver, thyroid and parathyroid diseases by laboratory tests.
Use of any hormone or herbal drug during the study period.
Irregular consumption or missing even one dose of vitamin D or placebo.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Anxiety Inventory.;Depression score. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: Beck Depression Inventory.;General Health. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the vitamin D or placebo). Method of measurement: General Health Questionnaire (GHQ).

Secondary Outcome Measures

Name	Time	Method
Frequency and severity of menopausal symptoms. Timepoint: At the beginning of the study and before the initial sampling, then at the end of the study (8 weeks after taking the drug or placebo). Method of measurement: The Menopause Rating Scale (MRS).